Cady K. Block
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Cady K. Block has a total of 151 co-authors. Here are the top co-authors by number of shared publications:
Jon T. Willie
Department of Neurosurgery, Washington University School of Medicine, St. Louis, MO 63110, USA
4 shared publications- Kelsey C. Hewitt
Department of Psychology, Prisma Health Roger C. Peace Rehabilitation Hospital, Greenville, SC, USA; Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA
4 shared publications - Daniel L. Drane
Department of Neurology, School of Medicine Emory University Atlanta Georgia USA
3 shared publications Robert E. Gross
Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA; Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA, USA; Coulter Department of Biomedical Engineering, Emory University, GA, USA
3 shared publicationsBenjamin B. Risk
Department of Biostatistics and Bioinformatics Emory University Rollins School of Public Health Atlanta Georgia USA
2 shared publicationsCathrin Buetefisch
Department of Neurology, Rehabilitation Medicine, and Radiology Emory University School of Medicine Atlanta Georgia USA
2 shared publications
Latest Publications
- 2 November 2026
- Published by Taylor & Francis in Neurocase
- p. 1-7
The neuropsychological profile of an individual with early-onset CSF1R-related disorder with biallelic mutation
- 2 November 2026
- Published by Taylor & Francis in Neurocase
- p. 1-7
The neuropsychological profile of an individual with early-onset CSF1R-related disorder with biallelic mutation
- 5 October 2026
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 143, 92-98
Epilepsy as a marker of cognitive decline in cerebral amyloid angiopathy: Evidence from a large multi-institutional cohort
- 5 October 2026
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 143, 92-98
Epilepsy as a marker of cognitive decline in cerebral amyloid angiopathy: Evidence from a large multi-institutional cohort
- 6 August 2025
- Published by Taylor & Francis
- p. 32-51
Drugs and Substance Abuse
As a result of an aging population, global incidence of pathological cognitive decline is rising. Considerable research has identified the long-term use of alcohol, tobacco, cannabis, opioid analgesics, and benzodiazepines as risk factors for cognitive impairment in middle-aged and older adults. In this chapter, we will review the association between drugs and substance abuse with declines in cognitive functioning, as well as the mechanisms underlying such changes. This chapter will also explore the potential reversibility of cognitive decline secondary to substance use. Particular emphasis is given to key practices in the identification and remediation of substance abuse, with the inclusion of a case study to highlight applicability to and presentation in clinical practice.
- 6 August 2025
- Published by Taylor & Francis
- p. 32-51
Drugs and Substance Abuse
As a result of an aging population, global incidence of pathological cognitive decline is rising. Considerable research has identified the long-term use of alcohol, tobacco, cannabis, opioid analgesics, and benzodiazepines as risk factors for cognitive impairment in middle-aged and older adults. In this chapter, we will review the association between drugs and substance abuse with declines in cognitive functioning, as well as the mechanisms underlying such changes. This chapter will also explore the potential reversibility of cognitive decline secondary to substance use. Particular emphasis is given to key practices in the identification and remediation of substance abuse, with the inclusion of a case study to highlight applicability to and presentation in clinical practice.
- 21 October 2024
- Published by Taylor & Francis in The Clinical Neuropsychologist
- Vol. 39 (6) , 1393-1416
New2Neuropsychology (N2N): An organization to promote diversity, equity, and inclusion in neuropsychology
To introduce New2Neuropsychology (N2N), an organization that seeks to increase recruitment of historically underrepresented minoritized (URM) students, and to examine preliminary data on N2N's impact and effectiveness in increasing knowledge about neuropsychology for URM students. This paper reviews relevant literature on factors informing the development of N2N. We also present descriptive data on N2N's impact to date, and results of pre- and post- surveys for presentations about neuropsychology delivered to 90 college students (mean age = 24.23, 64.4% juniors or seniors) between November 2021 - March 2023. N2N has reached >500 students in events across 27 schools and, with the American Academy of Clinical Neuropsychology, disseminated $84,000 in scholarships to URM students. N2N presentation attendees reported increased understanding of neuropsychology and the training pathway (ps < .001, Cohen's ds = 0.94 - 1.73) and increased confidence in their ability to become neuropsychologists (p < .001, d = 0.41). There were no overall pre-post differences for interest in pursuing a career in neuropsychology (p > .05); however, a subset of students who reported low interest at baseline (n = 57) reported a statistically significant increase in their interest post-presentation (p < .01, d = 0.36). To date, N2N has progressed toward its goal, showing preliminary success increasing knowledge about neuropsychology for URM students. With continued development and support, N2N seeks to transform the pathway to neuropsychology for URM students, expanding accessibility of N2N resources across diverse groups and connecting URM students to neuropsychology research and clinical experiences.
- 21 October 2024
- Published by Taylor & Francis in The Clinical Neuropsychologist
- Vol. 39 (6) , 1393-1416
New2Neuropsychology (N2N): An organization to promote diversity, equity, and inclusion in neuropsychology
To introduce New2Neuropsychology (N2N), an organization that seeks to increase recruitment of historically underrepresented minoritized (URM) students, and to examine preliminary data on N2N's impact and effectiveness in increasing knowledge about neuropsychology for URM students. This paper reviews relevant literature on factors informing the development of N2N. We also present descriptive data on N2N's impact to date, and results of pre- and post- surveys for presentations about neuropsychology delivered to 90 college students (mean age = 24.23, 64.4% juniors or seniors) between November 2021 - March 2023. N2N has reached >500 students in events across 27 schools and, with the American Academy of Clinical Neuropsychology, disseminated $84,000 in scholarships to URM students. N2N presentation attendees reported increased understanding of neuropsychology and the training pathway (ps < .001, Cohen's ds = 0.94 - 1.73) and increased confidence in their ability to become neuropsychologists (p < .001, d = 0.41). There were no overall pre-post differences for interest in pursuing a career in neuropsychology (p > .05); however, a subset of students who reported low interest at baseline (n = 57) reported a statistically significant increase in their interest post-presentation (p < .01, d = 0.36). To date, N2N has progressed toward its goal, showing preliminary success increasing knowledge about neuropsychology for URM students. With continued development and support, N2N seeks to transform the pathway to neuropsychology for URM students, expanding accessibility of N2N resources across diverse groups and connecting URM students to neuropsychology research and clinical experiences.
- 22 May 2024
- Published by Taylor & Francis in The Clinical Neuropsychologist
- Vol. 39 (1) , 218-232
A neuropsychological profile for high-grade primary central nervous system neuroendocrine tumor (CNS NET): A single-case study
Objective: Neuroendocrine tumors (NETs) are neoplasms that primarily occur in the lungs, appendix, small intestine, pancreas, and rectum, and typically metastasize to the liver or lymph nodes. However, in rare cases NETs can originate in the central nervous system (CNS). Understanding primary CNS NET neuropsychological manifestations aids in recommendations for neurocognitive follow-up, treatment and lifestyle planning, and future research. Method: Given the dearth of neuropsychological research for CNS NETs, we present a case seen in a 43-year-old woman. Results: Initial and 8-month follow-up neuropsychological evaluations of the patient revealed a Major Neurocognitive Disorder where the pattern of findings was consistent with tumor location and additional treatment-related factors. Reliable change indices at her re-evaluation revealed declines in verbal and visual memory, with statistical, yet not clinical, improvements in different domains. Follow-up monitoring of comprehensive care continued to occur after neuropsychological evaluations. Conclusions: This case study assists in the characterization of initial and follow-up neuropsychological presentation of a primary CNS NET, where evaluations helped inform clinical care and functional recommendations. This case demonstrates the importance for neuropsychologists to have awareness of various conditions, even rare conditions, which can inform a systematic approach to research and clinical care with neuro-oncological populations.
- 22 May 2024
- Published by Taylor & Francis in The Clinical Neuropsychologist
- Vol. 39 (1) , 218-232
A neuropsychological profile for high-grade primary central nervous system neuroendocrine tumor (CNS NET): A single-case study
Objective: Neuroendocrine tumors (NETs) are neoplasms that primarily occur in the lungs, appendix, small intestine, pancreas, and rectum, and typically metastasize to the liver or lymph nodes. However, in rare cases NETs can originate in the central nervous system (CNS). Understanding primary CNS NET neuropsychological manifestations aids in recommendations for neurocognitive follow-up, treatment and lifestyle planning, and future research. Method: Given the dearth of neuropsychological research for CNS NETs, we present a case seen in a 43-year-old woman. Results: Initial and 8-month follow-up neuropsychological evaluations of the patient revealed a Major Neurocognitive Disorder where the pattern of findings was consistent with tumor location and additional treatment-related factors. Reliable change indices at her re-evaluation revealed declines in verbal and visual memory, with statistical, yet not clinical, improvements in different domains. Follow-up monitoring of comprehensive care continued to occur after neuropsychological evaluations. Conclusions: This case study assists in the characterization of initial and follow-up neuropsychological presentation of a primary CNS NET, where evaluations helped inform clinical care and functional recommendations. This case demonstrates the importance for neuropsychologists to have awareness of various conditions, even rare conditions, which can inform a systematic approach to research and clinical care with neuro-oncological populations.
- 24 April 2024
- Published by Elsevier in Epilepsy & Behavior
- Vol. 155, 109669
Comparison of minimally invasive to standard temporal lobectomy approaches to epilepsy surgery: Seizure relief and visual confrontation naming outcomes
- 24 April 2024
- Published by Elsevier in Epilepsy & Behavior
- Vol. 155, 109669
Comparison of minimally invasive to standard temporal lobectomy approaches to epilepsy surgery: Seizure relief and visual confrontation naming outcomes
- 7 July 2023
- Published by Elsevier in Epilepsy & Behavior
- Vol. 145, 109332
Psychiatric changes after stereotactic laser amygdalohippocampotomy for medial temporal lobe epilepsy
- 7 July 2023
- Published by Elsevier in Epilepsy & Behavior
- Vol. 145, 109332
Psychiatric changes after stereotactic laser amygdalohippocampotomy for medial temporal lobe epilepsy
- 30 June 2023
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 10 (8) , 1235-1236
Reply: Deep Brain Stimulation Outcomes in Parkinson's Disease Patients with Cognitive Impairment: Implications and Considerations
- 30 June 2023
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 10 (8) , 1235-1236
Reply: Deep Brain Stimulation Outcomes in Parkinson's Disease Patients with Cognitive Impairment: Implications and Considerations
- Top Cited Papers
- 1 March 2023
- Published by American Psychological Association (APA) in Neuropsychology
- Vol. 37 (3) , 301-314
Development and application of the International Classification of Cognitive Disorders in Epilepsy (IC-CoDE): Initial results from a multi-center study of adults with temporal lobe epilepsy.
[Correction Notice: An Erratum for this article was reported online in Neuropsychology on Sep 15 2022 (see record 2023-01997-001). In the original article, there was an error in Figure 2. In the box at the top left of the figure, the fourth explanation incorrectly stated, "Generalized impairment = At least one test < -1.0 or -1.5SD in three or more domains." The correct wording is "Generalized impairment = At least two tests < -1.0 or -1.5SD in each of three or more domains." All versions of this article have been corrected.] Objective: To describe the development and application of a consensus-based, empirically driven approach to cognitive diagnostics in epilepsy research-The International Classification of Cognitive Disorders in Epilepsy (IC-CoDE) and to assess the ability of the IC-CoDE to produce definable and stable cognitive phenotypes in a large, multi-center temporal lobe epilepsy (TLE) patient sample. Neuropsychological data were available for a diverse cohort of 2,485 patients with TLE across seven epilepsy centers. Patterns of impairment were determined based on commonly used tests within five cognitive domains (language, memory, executive functioning, attention/processing speed, and visuospatial ability) using two impairment thresholds (≤1.0 and ≤1.5 standard deviations below the normative mean). Cognitive phenotypes were derived across samples using the IC-CoDE and compared to distributions of phenotypes reported in existing studies. Impairment rates were highest on tests of language, followed by memory, executive functioning, attention/processing speed, and visuospatial ability. Application of the IC-CoDE using varying operational definitions of impairment (≤ 1.0 and ≤ 1.5 SD) produced cognitive phenotypes with the following distribution: cognitively intact (30%-50%), single-domain (26%-29%), bi-domain (14%-19%), and generalized (10%-22%) impairment. Application of the ≤ 1.5 cutoff produced a distribution of phenotypes that was consistent across cohorts and approximated the distribution produced using data-driven approaches in prior studies. The IC-CoDE is the first iteration of a classification system for harmonizing cognitive diagnostics in epilepsy research that can be applied across neuropsychological tests and TLE cohorts. This proof-of-principle study in TLE offers a promising path for enhancing research collaborations globally and accelerating scientific discoveries in epilepsy. (PsycInfo Database Record (c) 2023 APA, all rights reserved).
- 1 March 2023
- Published by American Psychological Association (APA) in Neuropsychology
- Vol. 37 (3) , 301-314
Top Cited PapersDevelopment and application of the International Classification of Cognitive Disorders in Epilepsy (IC-CoDE): Initial results from a multi-center study of adults with temporal lobe epilepsy.
[Correction Notice: An Erratum for this article was reported online in Neuropsychology on Sep 15 2022 (see record 2023-01997-001). In the original article, there was an error in Figure 2. In the box at the top left of the figure, the fourth explanation incorrectly stated, "Generalized impairment = At least one test < -1.0 or -1.5SD in three or more domains." The correct wording is "Generalized impairment = At least two tests < -1.0 or -1.5SD in each of three or more domains." All versions of this article have been corrected.] Objective: To describe the development and application of a consensus-based, empirically driven approach to cognitive diagnostics in epilepsy research-The International Classification of Cognitive Disorders in Epilepsy (IC-CoDE) and to assess the ability of the IC-CoDE to produce definable and stable cognitive phenotypes in a large, multi-center temporal lobe epilepsy (TLE) patient sample. Neuropsychological data were available for a diverse cohort of 2,485 patients with TLE across seven epilepsy centers. Patterns of impairment were determined based on commonly used tests within five cognitive domains (language, memory, executive functioning, attention/processing speed, and visuospatial ability) using two impairment thresholds (≤1.0 and ≤1.5 standard deviations below the normative mean). Cognitive phenotypes were derived across samples using the IC-CoDE and compared to distributions of phenotypes reported in existing studies. Impairment rates were highest on tests of language, followed by memory, executive functioning, attention/processing speed, and visuospatial ability. Application of the IC-CoDE using varying operational definitions of impairment (≤ 1.0 and ≤ 1.5 SD) produced cognitive phenotypes with the following distribution: cognitively intact (30%-50%), single-domain (26%-29%), bi-domain (14%-19%), and generalized (10%-22%) impairment. Application of the ≤ 1.5 cutoff produced a distribution of phenotypes that was consistent across cohorts and approximated the distribution produced using data-driven approaches in prior studies. The IC-CoDE is the first iteration of a classification system for harmonizing cognitive diagnostics in epilepsy research that can be applied across neuropsychological tests and TLE cohorts. This proof-of-principle study in TLE offers a promising path for enhancing research collaborations globally and accelerating scientific discoveries in epilepsy. (PsycInfo Database Record (c) 2023 APA, all rights reserved).
- 30 January 2023
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 10 (3) , 382-391
Patients with Cognitive Impairment in Parkinson's Disease Benefit from Deep Brain Stimulation: A Case‐Control Study
Background: Deep brain stimulation (DBS) for Parkinson's disease (PD) is generally contraindicated in persons with dementia but it is frequently performed in people with mild cognitive impairment or normal cognition, and current clinical guidelines are primarily based on these cohorts.Objectives: To determine if moderately cognitive impaired individuals including those with mild dementia could meaningfully benefit from DBS in terms of motor and non‐motor outcomes.Methods: In this retrospective case‐control study, we identified a cohort of 40 patients with PD who exhibited moderate (two or more standard deviations below normative scores) cognitive impairment (CI) during presurgical workup and compared their 1‐year clinical outcomes to a cohort of 40 matched patients with normal cognition (NC). The surgery targeted subthalamus, pallidus or motor thalamus, in a unilateral, bilateral or staged approach.Results: At preoperative baseline, the CI cohort had higher Unified Parkinson's Disease Rating Scale (UPDRS) subscores, but similar levodopa responsiveness compared to the NC cohort. The NC and CI cohorts demonstrated comparable degrees of postoperative improvement in the OFF‐medication motor scores, motor fluctuations, and medication reduction. There was no difference in adverse event rates between the two cohorts. Outcomes in the CI cohort did not depend on the target, surgical staging, or impaired cognitive domain.Conclusions: Moderately cognitively impaired patients with PD can experience meaningful motor benefit and medication reduction with DBS.
- 30 January 2023
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 10 (3) , 382-391
Patients with Cognitive Impairment in Parkinson's Disease Benefit from Deep Brain Stimulation: A Case‐Control Study
Background: Deep brain stimulation (DBS) for Parkinson's disease (PD) is generally contraindicated in persons with dementia but it is frequently performed in people with mild cognitive impairment or normal cognition, and current clinical guidelines are primarily based on these cohorts.Objectives: To determine if moderately cognitive impaired individuals including those with mild dementia could meaningfully benefit from DBS in terms of motor and non‐motor outcomes.Methods: In this retrospective case‐control study, we identified a cohort of 40 patients with PD who exhibited moderate (two or more standard deviations below normative scores) cognitive impairment (CI) during presurgical workup and compared their 1‐year clinical outcomes to a cohort of 40 matched patients with normal cognition (NC). The surgery targeted subthalamus, pallidus or motor thalamus, in a unilateral, bilateral or staged approach.Results: At preoperative baseline, the CI cohort had higher Unified Parkinson's Disease Rating Scale (UPDRS) subscores, but similar levodopa responsiveness compared to the NC cohort. The NC and CI cohorts demonstrated comparable degrees of postoperative improvement in the OFF‐medication motor scores, motor fluctuations, and medication reduction. There was no difference in adverse event rates between the two cohorts. Outcomes in the CI cohort did not depend on the target, surgical staging, or impaired cognitive domain.Conclusions: Moderately cognitively impaired patients with PD can experience meaningful motor benefit and medication reduction with DBS.